Faruqi & Faruqi Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 – EW

Core Viewpoint - Edwards Lifesciences Corporation is facing a federal securities class action due to allegations of misleading statements regarding its revenue expectations for the fiscal year 2024, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) platform [3][4]. Group 1: Legal Action and Claims - Faruqi & Faruqi, LLP is investigating potential claims against Edwards and has set a deadline of December 13, 2024, for investors to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Edwards and its executives violated federal securities laws by failing to disclose material information about the expected revenue growth of TAVR [3]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year [4]. - Following the announcement, Edwards' stock price plummeted from $86.95 per share to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in one day [5]. Group 3: Company Strategy and Market Dynamics - The company attributed the TAVR revenue setback to increased competition from new structural heart therapies, which strained hospital workflows and led to underutilization of TAVR [4]. - Edwards announced three acquisitions during Q2 2024 aimed at enhancing its treatment alternatives to TAVR, indicating a strategic pivot in response to the challenges faced by the TAVR platform [4].